This announcement is not for release, publication or distribution in the United
States, Canada, Australia or Japan. This announcement is not an offer of
securities for sale in the United States or elsewhere.
Announcement no. 18/2007
To OMX the Nordic Exchange
Copenhagen, July 4, 2007
Full exercise of overallotment option
Summary: Danske Markets exercises the overallotment option of 2,000,000 shares
in Curalogic A/S. The gross proceeds to the company will be DKK 34 million.
Curalogic A/S hereby announces that it has been notified that Danske Markets
wishes to exercise the overallotment option of 2,000,000 shares as described in
the company's prospectus dated June 8, 2007 regarding the company's offering of
18,000,000 new shares.
The additional 2,000,000 shares from the overallotment option will be issued by
the company. The shares have been sold to institutional investors at a price
corresponding to the offer price of DKK 17 per share, and the gross proceeds to
Curalogic will be DKK 34 million. Following the issue of the overallotment
shares, Curalogic's share capital will total DKK 28,214,408 consisting of
56,428,816 shares with a nominal value of DKK 0.50 each.
Danske Markets (department of Danske Bank A/S) was Global Co-ordinator &
Bookrunner and Piper Jaffray Ltd. was Co-Lead Manager in connection with the
offering.
Danske Markets has announced that they have carried out stabilisation in
Curalogic A/S on June 25, 2007 in the price range 16.90 - 17.00 and on June 26,
2007 in the price range 16.80 - 17.00.
The shares from the overallotment option will be registered with the Danish
Commerce and Companies Agency as soon as possible.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange Copenhagen (CUR.CO). Curalogic develops innovative pharmaceuticals for
the treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for
treatment of house dust mite allergy preparing for clinical trials.
DISCLAIMER
It may be unlawful to distribute this announcement in certain jurisdictions.
This announcement is not for distribution in the United States, Canada,
Australia or Japan. The information in this announcement does not constitute an
offer of securities for sale in the United States, Canada, Australia or Japan.
The Company does not intend to register securities in the United States or to
conduct a public offering of securities in the United States. Securities may not
be offered or sold in the United States unless they are registered or are exempt
from registration.
